Compare BIO-TECHNE Corp (TECH) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Tripadvisor Inc Common Stock — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Tripadvisor Inc Common Stock trades at $8.77 (market cap $1.07B). The key difference: BIO-TECHNE Corp is far larger — about 10.6× Tripadvisor Inc Common Stock's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| TECH | TRIP | |
|---|---|---|
Market Cap | $11.34B | $1.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $72.48 | $19.14 |
52-Week Low | $43.31 | $8.82 |
Enterprise Value | $11.36B | $1.12B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Tripadvisor (TRIP) trades at $9.085, down 2.57% for the day, reflecting ongoing pressure from recent earnings misses and competitive challenges. The stock shows bearish technical signals with mixed oscillators, while fundamentals reveal strong gross margins (92.11%) but thin net income (0.27%). Recent news highlights insider selling and TheFork subsidiary sale, creating uncertainty about growth prospects amid AI-driven travel competition.
The outlook remains cautious with analyst consensus leaning Hold (62.5%) despite a $11.80 price target suggesting 30% upside. Key risks include persistent earnings volatility, market share erosion to AI platforms, and declining cash flow trends. Investment opportunity hinges on Viator's performance and successful execution of strategic initiatives post-TheFork divestiture.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
